Dendreon Falls on Provenge Forecast Withdrawal

Play

Aug. 4 (Bloomberg) -- Dendreon Corp., maker of the prostate-cancer drug Provenge, plunged 58 percent in early trading after the company withdrew its 2011 revenue estimate and said sales of the medicine didn?t meet projections. Shannon Pettypiece reports on Bloomberg Television's "In the Loop." (Source: Bloomberg)